Transdermal dopaminergic D2receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study

Autor: Hutton, J. Thomas, Metman, Leo Verhagen, Chase, Thomas N., Juncos, Jorge L., Koller, William C., Pahwa, Rajesh, LeWitt, Peter A., Samii, Ali, Tsui, Joseph K.C., Calne, Donald B., Waters, Cheryl H., Calabrese, Vincent P., Bennett, James P., Barrett, Richard, Morris, Jerry L.
Zdroj: Movement Disorders; May 2001, Vol. 16 Issue: 3 p459-463, 5p
Abstrakt: N‐0923 is a non‐ergot, dopaminergic D2agonist designed to be transdermally available. It has anti‐parkinsonian effects when infused intravenously. An adhesive matrix patch was developed to deliver N‐0923 transdermally (N‐0923 TDS).
Databáze: Supplemental Index